United Therapeutics announces settlement of patent litigation with Watson Laboratories
United Therapeutics announced a Settlement Agreement with Watson Laboratories resolving ongoing litigation concerning certain patents relating to United Therapeutics' product, Tyvaso® (treprostinil) Inhalation Solution, and Watson's ANDA seeking FDA approval to market a generic version of Tyvaso. August 09, 2018
